全球单株抗体治疗市场规模、份额和成长分析：按类型、按应用分类 - 产业预测（2023-2030）

Global Monoclonal Antibody Therapy Market Size, Share, Growth Analysis, By Type(Murine Antibodies, Chimeric Antibodies), By Application(Oncology, Autoimmune Diseases) - Industry Forecast 2023-2030

出版日期: 2023年10月09日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2021年全球单株抗体治疗市场规模为1,338亿美元，预计将从2022年的1,435.7亿美元增加到2030年的2,522.6亿美元，年复合成长率预计为7.3%。

市场的主要驱动力之一是癌症、自体免疫疾病和心血管疾病等慢性疾病的流行。单株抗体疗法在治疗这些疾病方面已显示出有希望的结果，并且越来越多的采用。此外，高龄化和文明病的增加也进一步促进了市场的成长。技术的进步使得高度特异性和有效的抗体的生产成为可能，从而提高了治疗效果。此外，对个人化医疗和标靶治疗的日益关注进一步推动了对单株抗体治疗的需求。

全球单株抗体治疗市场动态

全球单株抗体治疗市场的驱动因素

生物技术和基因工程的进展

生物技术和基因工程的重大进步在先进单株抗体治疗的开发中发挥关键作用。这些进步促进了抗体的生产，提高了特异性、功效并减少了副作用。基因工程等技术使研究人员能够针对特定标靶最佳化单株抗体，从而提高其治疗潜力。这些突破正在扩大单株抗体的应用范围并提高其治疗的成功率。

全球单株抗体治疗市场的抑制因素

可能的副作用和安全性问题

与任何医疗介入一样，单株抗体治疗可能会产生副作用和安全性问题。有些患者可能会出现药物相关反应，包括输液相关反应。此外，还存在潜在的免疫抗原性，即患者的免疫系统对治疗产生免疫反应。当治疗药物与体内非预期目标相互作用时，也可能发生脱靶效应。密切监测和解决这些安全问题对于确保患者健康、维持治疗信心和遵守法规标准至关重要。持续监控、稳健的安全评估以及潜在风险的清晰沟通对于有效管理这些问题至关重要。

全球单株抗体治疗的趋势

越来越多地采用和开发个体化和标靶治疗：单株抗体疗法在治疗多种疾病（包括癌症、自体免疫疾病和感染疾病）方面正在获得显着的发展势头。伴随诊断、基因分析和生物标记识别等个人化医疗方法正在被整合到单株抗体治疗的开发和发展中。这种趋势允许更精确和客製化的治疗方法，最大限度地提高治疗效果，同时最大限度地减少副作用。

本报告针对全球单株抗体治疗市场进行研究分析，提供市场动态与前景、細項分析、公司简介等。

Roche Holding AG (Switzerland)
Johnson & Johnson (US)
Novartis International AG (Switzerland)
Pfizer Inc. (US)
Merck & Co., Inc. (US)
Amgen Inc. (US)
AstraZeneca PLC (UK)
Bristol Myers Squibb Company (US)
AbbVie Inc. (US)
Eli Lilly and Company (US)
Sanofi SA (France)
GlaxoSmithKline plc (UK)
Takeda Pharmaceutical Company Limited (Japan)
Biogen Inc. (US)
Regeneron Pharmaceuticals, Inc. (US)
Moderna, Inc. (US)
BioNTech SE (Germany)
Alexion Pharmaceuticals, Inc. (US)
Gilead Sciences, Inc. (US)
CSL Limited (Australia)

简介目录

Product Code: SQMIG35A2527

Global Monoclonal Antibody Therapy Market size was valued at USD 133.8 billion in 2021 and is poised to grow from USD 143.57 billion in 2022 to USD 252.26 billion by 2030, growing at a CAGR of 7.3% in the forecast period (2023-2030).

One of the primary drivers of the global monoclonal antibody therapy market is the increasing prevalence of chronic diseases, such as cancer, autoimmune disorders, and cardiovascular diseases. Monoclonal antibody therapies have shown promising results in the treatment of these conditions, leading to their growing adoption. Additionally, the aging population and the rise in lifestyle-related diseases have further contributed to the market growth. Technological advancements have enabled the production of highly specific and effective antibodies, increasing their therapeutic efficacy. Additionally, the growing focus on personalized medicine and targeted therapies has further fueled the demand for monoclonal antibody therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Monoclonal Antibody Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Monoclonal Antibody Therapy Market Segmental Analysis

The global monoclonal antibody therapy market is segmented based on type, application, and region. Based on type, the market can be segmented into Murine Antibodies, Chimeric Antibodies, Humanised Antibodies, and Fully Human Antibodies. Based on application, the market is segmented into Oncology, Autoimmune Diseases, Infectious Diseases, Inflammatory Conditions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Monoclonal Antibody Therapy Market Dynamics

Drivers of the Global Monoclonal Antibody Therapy Market

Advancements in Biotechnology and Genetic Engineering

Significant progress in biotechnology and genetic engineering has played a pivotal role in the development of advanced monoclonal antibody therapies. These advancements have facilitated the engineering of antibodies with improved specificity, efficacy, and reduced side effects. Through techniques such as genetic manipulation, researchers can optimise monoclonal antibodies for specific targets, enhancing their therapeutic potential. These breakthroughs have broadened the range of applications for monoclonal antibody therapies and increased their success rates.

Restraints in the Global Monoclonal Antibody Therapy Market

Potential Side Effects and Safety Concerns

Like any medical intervention, monoclonal antibody therapies carry the potential for side effects and safety concerns. Some patients may experience reactions related to the administration of the therapy, such as infusion-related reactions. Additionally, there is a possibility of immunogenicity, where the patient's immune system may mount an immune response against the therapy. Off-target effects, where the therapy may interact with unintended targets in the body, can also occur. It is crucial to closely monitor and address these safety concerns to ensure patient well-being, maintain confidence in the therapy, and adhere to regulatory standards. Continuous monitoring, robust safety assessment, and clear communication of potential risks are vital in managing these concerns effectively.

Market Trends of Global Monoclonal Antibody Therapy Key

Increasing Adoption and Development of Personalised and Targeted Therapies: Monoclonal antibody therapies have gained significant momentum in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. Personalised medicine approaches, such as companion diagnostics, genetic profiling, and biomarker identification, are being integrated into the development and prescription of monoclonal antibody therapies. This trend allows for a more precise and tailored treatment approach, maximising therapeutic efficacy while minimising adverse effects.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
- Regulatory Landscape
- Porters Analysis
Competitive rivalry
Threat of Substitute Products
Bargaining Power of Buyers
Threat of New Entrants
Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
Political Impact
Economic Impact
Social Impact
Technical Impact
Environmental Impact
Legal Impact
Global Monoclonal Antibody Therapy Market by Type
- Market Overview
- Murine Antibodies
- Chimeric Antibodies
- Humanised Antibodies and Fully Human Antibodies
Global Monoclonal Antibody Therapy Market by Application
- Market Overview
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Inflammatory Conditions and Others.
Global Monoclonal Antibody Therapy Market Size by Region
- Market Overview
- North America
USA
Canada
- Europe
Germany
Spain
France
UK
Rest of Europe
- Asia Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
- Latin America
Brazil
Rest of Latin America
- Middle East & Africa (MEA)
GCC Countries
South Africa
Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
By Development
By Company
By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Roche Holding AG (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Johnson & Johnson (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Novartis International AG (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Pfizer Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Merck & Co., Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Amgen Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- AstraZeneca PLC (UK)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Bristol Myers Squibb Company (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- AbbVie Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Eli Lilly and Company (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sanofi S.A. (France)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- GlaxoSmithKline plc (UK)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Biogen Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Regeneron Pharmaceuticals, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Moderna, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- BioNTech SE (Germany)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Alexion Pharmaceuticals, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Gilead Sciences, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- CSL Limited (Australia)
Company Overview
Business Segment Overview
Financial Updates
Key Developments